References
- Alper KR, Stajic M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci. 2012;57:398–412.
- Obach RS, Pablo J, Mash DC. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos. 1998;26:764–768.
- Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20:2208–2228.
- Yip L, Deng JF. On the toxicity of ibogaine. Clin Toxicol. 2016;54:605.
- Hildyard C, Macklin P, Prendergast B, et al. A case of QT prolongation and torsades de pointes caused by ibogaine toxicity. J Emerg Med. 2016;50:83–87.
- Baumann MH, Pablo JP, Ali SF, et al. Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine. Ann N Y Acad Sci. 2000;914:354–368.
- Asua I. Growing menace of ibogaine toxicity. Br J Anaesth. 2013;111:1029–1030.
- Litjens RPW, Brunt TM. How toxic is ibogaine? Clin Toxicol. 2016;54:297–302.
- Glue P, Lockhart M, Lam F, et al. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. 2015;55:189–194.
- Mash DC, Kovera CA, Pablo J, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001;56:155–171.
- Kontrimaviciute V, Mathieu O, Mathieu-Daude JC, et al. Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub. J Anal Toxicol. 2006;30:434–440.
- Alliance. GIT. Clinical Guidelines for Ibogaine-Assisted Detoxification [Internet]. 2016 [updated Febuary 2016; cited 2016]. Available from: https://www.ibogainealliance.org/guidelines/